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Objectives: In the last decade gut microbial diversity was associated with the pathogenesis of obesity 
in humans. Plasma citrulline was a simple and accurate biomarker for the severity of intestinal 
failure and was associated with short bowel syndrome and alteration of gut permeability, being 
developed as an alternative to D-xylose tolerance test for the diagnosis of an abnormal small 
intestinal absorption of nutrients. This study was performed to ascertain whether obesity might 
be associated with dysregulation of epithelial gut function. Methods: Fifteen obese individuals (5 
M/10 F; BMI 37.4 ± 6.1 Kg/m2; 42 ± 6 yrs) and 15 healthy gender- and age-matched controls (6 
M/9 F BMI: 22.7 ± 2.1 Kg/m2; 39 ± 7 yrs) underwent D-xylose load (25 g) and plasma citrulline, 
plasma insulin, glucose and lipid profile testing. Results: Plasma citrulline was significantly lower 
in the obese group (p = 0.045) with respect to controls, whilst total cholesterol, LDL and trygliceri- 
des concentration, insulin level and HOMA-IR were significantly higher in obese patients. In contrast, 
after D-xylose load no difference in serum xylose was found between the two groups (p = ns). 
Conclusions: Obese patients show a decreased citrulline concentration with respect to lean subjects. 
Since citrulline is a known marker of intestinal health, alterations in the gut epithelium are likely 
to be associated with the obesity syndrome. We propose to measure citrulline level in obese patients 
on a routine basis. 
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Overweight and obesity are major risk factors for a number of chronic-degenerative diseases. In the last decade 
gut microbial diversity was associated to the pathogenesis of obesity in humans [1] [2]. It has been previously 
shown that in patients with short bowel syndrome, plasma citrulline is a biomarker for the severity of intestinal 
failure [3]. Citrulline is an amino acid released exclusively from small bowel enterocytes and its blood level is 
highly dependent on small bowel enterocytes mass. In several intestinal diseases there is an alteration of micro-
flora which can play an important role in initiation of the disease. Another methodology to assess gut physiology 
is D-xylose test. The D-xylose test is an excellent serologic test for the diagnosis of important inflammatory 
intestinal conditions such as celiac disease [4]. In contrast, plasma citrulline concentration is a simple and relia-
ble surrogate for small bowel absorptive capacity and is not influenced by intestinal inflammation. 
2. Subjects and Methods 
2.1. Subjects 
Fifteen obese patients without diabetes mellitus, dyslipidemia and in stable condition were recruited in the pop-
ulation of over 600 patients at the Nutrition/Metabolism Unit of San Raffaele Hospital. A BMI of ≥30 kg/m2 
was used for obesity classification. Fifteen healthy volunteers, matched for anthropometric parameters, served as 
a control group. All the subjects were recruited between July 2007 and January 2008. Table 1 represents the 
anthropometry of study-subjects. The Ethics Committee of San Raphael Scientific Institute (Milan, Italy) ap-
proved the experimental protocol, and written informed consent was obtained from all patients.  
2.2. Experimental Protocol 
All subjects involved in this protocol were studied on two separate days. The subjects assumed an isocaloric diet 
in the 4 weeks preceding the study. On day 1, they were admitted to the Metabolic Unit of the Department of 
Medicine of San Rafael Scientific Institute after an overnight fast. At 08.00 of day 1, a polyethylene catheter 
was inserted in the antecubital vein of one forearm. At 08.30, a basal blood sample for the measurement of hor-
mones and metabolites was drawn and the urinary cortisol concentration was measured in the total urine speci-
men collected over the preceding 24 hours. Then the patients were discharged. On day 2, all subjects were re- 
admitted to the San Raffaele Hospital and underwent a D-xylose load (25 g) as well a blood sample for mea-
surement of plasma citrulline concentration. 
2.3. Analytical Methods 
Aliquots of blood for the measurement of metabolites (glucose, triglycerides, total cholesterol, HDL cholesterol, 
LDL cholesterol, TSH) level were placed in heparinized tubes. Plasma glucose was measured utilizing the glu-
cose oxidase methodology. Blood aliquots for insulin and TSH were collected in tubes for serum separation. 
Urine collection (24 h) was performed to quantify cortisol excretion. All blood samples were placed in ice until 
the plasma/serum was prepared by centrifugation at 4˚C (within 1.5 h of sampling). All plasma and serum ali-
quots were frozen at −60˚C until later analysis. 
2.4. D-Xylose Test 
All subjects ingested an oral solution composed by 25 g of D-xylose in 250 ml of water. Blood samples were 
drawn and measured for D-xylose concentration at baseline and at 120 minutes after xylose ingestion. 
 
Table 1. Anthropometrical and clinical characteristics of the subjects.                                              
Subject characteristics Obese patients Controls 
Sex (M/F) 5/10 6/9 
Age (y) 42 ± 6 39 ± 7 
Weight (kg) 97 ± 22* 69 ± 15 
Height (cm) 160 ± 8 165 ± 9 
BMI (kg/m2) 37.4 ± 6.1* 22.7 ± 2.1 
*p < 0.001 vs. CON. 
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2.5. Citrulline Determination 
Plasma levels of the amino acid were obtained using an adaptation of an HPLC procedure based on pre-column 
derivatization with o-phthaldialdehyde (OPA) and carried out on reversed-phase C18 column [5]. 
2.6. Statistical Analysis 
All data are expressed as means ± SD. Comparisons between obese and control groups were performed with the 
Student’s t-test for unpaired data (a value of less than 0.05 was considered statistically significant). We used non 
parametric methods (Mann-Whitney test) to compare HOMA-IR in the groups because the distribution of these 
dependent variable were not normal.  
3. Results (See Table 2) 
3.1. D-Xylose Test 
No difference was observed in the xylosemia between the two study groups. In particular the obese group had a 
value of xylosemia slightly lower compared to controls. 
3.2. Insulin Action 
The HOMA-IR was higher in obese group with respect to controls (p < 0.03). 
3.3. Plasma Citrulline 
Plasma citrulline concentration was lower in obese patients with respect to controls (p = 0.045), indicating a re-
duction of production of this amino-acid by small bowel epithelium. 
3.4. Lipid Profile 
Plasma lipid profile was normal in obese patients and in control group. The total cholesterol was higher in obese 
group (p < 0.01). Also triglyceride concentrations were higher in obese group (p < 0.01).  
3.5. Hormones 
Plasma insulin was higher in the obese group with respect to controls (p < 0.01). The free urinary cortisol was 
normal in obese patients but within the upper 50% of the normal range (p = 0.07).  
 
Table 2. Mean + SD of lipids, hormones, insulin sensitivity index, plasma citrulline and xylose in obese patients and in con-
trol subjects.                                                                                              
 Obese patients Controls 
Plasma glucose (mmol/l) 4.7 ± 0.6 5 ± 0.3 
Free insulin (pmol/l) 49.8* ± 15.06 30.5 ± 10.1 
Total cholesterol (mmol/l) 5.2* ± 0.4 4.4 ± 0.3 
Cholesterol HDL 1.3 ± 0.3 1.4 ± 0.2 
Cholesterol LDL (calculated) 3.4* ± 1.4 2.6 ± 1.1 
Triglycerides (mmol/l) 1.3* ± 0.9 0.7 ± 0.4 
HOMA-IR 1.75* ± 0.93 0.98 ± 0.44 
Blood D-xylose (mmol/L) 2.82 ± 0.76 3.21 ± 0.89 
Plasma citrulline (mmol/L) 22.3* ± 6.2 26.3 ± 3.9 
Free urinary cortisol (nmol/24 h) 342 ± 74 296 ± 63 
TSH (mU/l) 1.72 ± 0.90 1.92 ± 1.03 
*p < 0.05 vs. CON. 




The current study presents a new observation regarding the possibility that obesity may be associated with dy-
sregulation of epithelial gut function. 
It is well known that intestinal microflora and diet influence both body weight and insulin-resistance, notably 
through an action on adipose cells [6]. Indeed, it has been suggested that a person’s gut microbiota has a specific 
metabolic efficiency and that certain characteristics of the microbiota composition might predispose to obesity 
[2].  
The gut epithelium is not only involved in the absorption of nutrients, but must also provide a barrier between 
the gastrointestinal lumen and the rest of the body.  
In our study, all obese subjects were insulin resistant and with alteration of gut epithelium, possibly of in-
flammatory origin. 
In patients with intestinal transplantation low value of blood citrulline is now considered a marker of graft 
dysfunction (acute rejection) [7]. 
In animal model citrulline supplementation improved gut function by decreasing intestinal permeability and 
positively affecting immune function [8]. 
In the same fashion the alterations present in obese patients seem to be similar to patients with early stage of 
graft rejection. 
One possible explanation of our results in the obese subjects may be the presence of chronic inflammation in 
the epithelium of gut.  
Therapies of obesity have focused on reducing caloric intake, decreasing nutrient absorption, or increasing 
physical activity. Future treatments for obesity may attempt to modulate the intestinal microbiota through the 
use of antibiotics, probiotics, and prebiotics [9]. 
5. Conclusions and Limitations 
In conclusion, our results indicate that there is a strict correlation between the characteristic metabolic picture 
present in obesity and low value of citrulline (a marker of integrity of gut epithelium). In accordance with other 
authors [10] [11], we showed in humans the presence of epithelium gut alteration in obesity.  
There are some possible limitations to consider in the present study. First, the number of obesity in the sample 
is somewhat small. Second, this is a case-control study and we cannot draw a cause-effect conclusion about ga-
strointestinal alteration and obesity. 
Further studies are needed to elucidate the potential role of citrulline as useful biomarker to label patients af-
fected by obesity as patients with dysregulation of epithelial gut absorption.  
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